Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
Experiments in vitro demonstrate that these novel SMO inhibitors potentially suppress the growth of cancer cells and inhibit the expression of the HH/PTCH pathway genes. More
The technology consists of markers whose expression discriminates between patients with prostate cancer and patients without at a rate of 95% correct diagnosis, and between localised and metastatic prostate cancer with a correct diagnosis of 85%. More
Exclusive license for use of gabapentin in the above indications in EU, Canada, Australia, New Zealand. US Phase 3 trials of MR-gabapentin for menopause by PharmaNova’s US licensee (Depomed, Inc) will complete in 3Q 2009; Co-promotion in US is possible. More
US based researchers are seeking licensing partners for the further development of their antigen which is intended for the treatment of breast cancer but could also have applications in ovarian cancer and other malignancies. More
Displaying 1..10 of 35 -
per page
Next page
Order by
All rights reserved. Terms and Conditions | Contact us
